Análisis de simulación de coste-efectividad en el tratamiento de la esquizofrenia en el Instituto Mexicano del Seguro Social. Evaluación de antipsicóticos típicos y atípicos

• Joaquín Mould-Quevedo ^[1] ; Iris Contreras-Hernández ^[1] ; Wáscar Verduzco ^[2] ; Juan Manuel Mejía-Aranguré ^[3] ; Juan Garduño-Espinosa ^[1]
  1. [1] Instituto Mexicano del Seguro Social

     Instituto Mexicano del Seguro Social

     México

     
  2. [2] Hospital de Psiquiatría, IMSS, Ciudad de México, México
  3. [3] Unidad de Investigación en Epidemiología Clínica, Hospital de Alta Especialidad Médica, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, IMSS, Ciudad de México, México

  Mostrar afiliaciones +
• Localización: Revista de psiquiatría y salud mental, ISSN 1888-9891, ISSN-e 1989-4600, Vol. 2, Nº. 3, 2009, págs. 108-118
• Idioma: español
• Títulos paralelos:
  • Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics
• Enlaces
  • Texto completo
• Resumen
  • español

    Introduction: Estimation of the economic costs of schizophrenia is a fundamental tool for a better understanding of the magnitude of this health problem. The aim of this study was to estimate the costs and effectiveness of five antipsychotic treatments (ziprasidone, olanzapine, risperidone, haloperidol and clozapine), which are included in the national formulary at the Instituto Mexicano del Seguro Social, through a simulation model. Methods: Type of economic evaluation: complete economic evaluation of cost-effectiveness. Study perspective: direct medical costs. Time horizon: 1 year. Effectiveness measure: number of months free of psychotic symptoms. Analysis: to estimate cost-effectiveness, a Markov model was constructed and a Monte Carlo simulation was carried out. Results: Effectiveness: the results of the Markov model showed that the antipsychotic with the highest number months free of psychotic symptoms was ziprasidone (mean 9.2 months). The median annual costs for patients using ziprasidone included in the hypothetical cohort was 194,766.6 Mexican pesos (MXP) (95% CI, 26,515.6-363,017.6 MXP), with an exchange rate of 1 = 17.36 MXP. The highest costs in the probabilistic analysis were estimated for clozapine treatment (260,236.9 MXP). Conclusions: Through a probabilistic analysis, ziprasidone showed the lowest costs and the highest number of months free of psychotic symptoms and was also the most cost-effective antipsychotic observed in acceptability curves and net monetary benefits.

  • English

    Introduction: Estimation of the economic costs of schizophrenia is a fundamental tool for a better understanding of the magnitude of this health problem. The aim of this study was to estimate the costs and effectiveness of ive antipsychotic treatments (ziprasidone, olanzapine, risperidone, haloperidol and clozapine), which are included in the national formulary at the Instituto Mexicano del Seguro Social, through a simulation model.Methods: Type of economic evaluation: complete economic evaluation of cost-effectiveness. Study perspective: direct medical costs. Time horizon: 1 year. Effectiveness measure: number of months free of psychotic symptoms. Analysis: to estimate cost-effectiveness, a Markov model was constructed and a Monte Carlo simulation was carried out.Results: Effectiveness: the results of the Markov model showed that the antipsychotic with the highest number months free of psychotic symptoms was ziprasidone (mean 9.2 months). The median annual costs for patients using ziprasidone included in the hypothetical cohort was 194,766.6 Mexican pesos (MXP) (95% CI, 26,515.6-363,017.6 MXP), with an exchange rate of 1 € = 17.36 MXP. The highest costs in the probabilistic analysis were estimated for clozapine treatment (260,236.9 MXP). Conclusions: Through a probabilistic analysis, ziprasidone showed the lowest costs and the highest number of months free of psychotic symptoms and was also the most cost-effective antipsychotic observed in acceptability curves and net monetary benefits.